Slow-release pharmaceutical composition for treating cardiomyopathy and preparation device thereof

Abstract

The invention relates to the technical field of biological medicines, in particular to a sustained-release pharmaceutical composition for treating cardiomyopathy and a preparation device thereof. An existing preparation is fast in metabolism and difficult to act for a long time in myocardial tissue. Every 10 ml of the pharmaceutical composition comprises 1 g of levocarnitine as a raw material medicine, 48 mg of sodium benzoate, 34 mg of DL-malic acid and 5 mg of saccharin sodium as auxiliary materials, hydrochloric acid used for adjusting the PH value to 4.3-4.7, and purified water added to 10 ml. Through an auxiliary material system in the composition, especially DL-malic acid, the release rate of the medicine can be adjusted, and a physical and chemical basis is provided for realizing a slow release effect, so that the medicine can be released more gently in vivo, and the effective blood concentration of the medicine can be maintained for a longer time, thereby achieving the purpose of continuously supplying energy to myocardial cells, and further achieving the aim of continuously supplying energy to the myocardial cells. The defects that the half-life period is short and the drug effect is not continuous in the prior art are overcome.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of biological medicine, and particularly relates to a sustained-release drug composition for treating cardiomyopathy and a preparation device thereof. BACKGROUND

[0002] Cardiomyopathy is a disease caused by abnormal structure or function of heart muscle, which leads to mechanical and electrical activity disorders of myocardium. The clinical manifestations are various, and common symptoms include heart failure, arrhythmia, dyspnea, etc. Energy metabolism of myocardium is the key to maintain normal function of heart. As the main energy source of heart, beta-oxidation of fatty acid plays an important role in energy supply of myocardial cells. This process is seriously dependent on transport of levocarnitine, because levocarnitine can transport long-chain fatty acids into mitochondria for oxidative decomposition, so as to provide sustained energy supply for myocardial cells.

[0003] At present, the commonly used levocarnitine drugs in clinic are mostly ordinary oral liquid or injection. These existing preparations have obvious limitations. Firstly, the half-life of levocarnitine in human body is short, so that the ordinary preparation cannot maintain stable blood drug concentration, the drug efficacy fluctuates greatly, and the patient needs frequent medication, so the compliance is poor. Secondly, the ordinary preparation is metabolized quickly after absorption, and it is difficult to achieve long-acting effect of the drug in myocardial tissue, which limits the maximization of the improvement effect of myocardial energy metabolism. In addition, the ordinary preparation has poor targeting, and the drug is unevenly distributed in the whole body circulation, which affects the treatment effect. SUMMARY

[0004] In order to overcome the shortcomings mentioned in the background, the present application provides a sustained-release drug composition for treating cardiomyopathy and a preparation device thereof.

[0005] The technical scheme of the present application is: a sustained-release drug composition for treating cardiomyopathy, characterized in that 10ml of the drug composition comprises raw material drug: levocarnitine 1g, auxiliary drug: sodium benzoate 48mg, DL-malic acid 34mg, sodium saccharin 5mg, hydrochloric acid for adjusting PH value to 4.3-4.7, purified water, and adding to 10ml.

[0006] The utility model relates to a slow release medicine composition preparation device for treating cardiomyopathy, including the shell, the shell fixedly connected with liquid inlet pipe, liquid outlet pipe and blowdown pipe, the shell fixedly connected with baffle and fixed plate in, the baffle with the fixed plate between detachably connected with annular array a plurality of filter core, the baffle will the shell is divided into two cavities, the shell's two cavities are communicated through a plurality of filter core, the liquid inlet pipe with the shell's upper cavity is communicated, the blowdown pipe passes through the baffle with the shell's upper cavity is communicated, the liquid outlet pipe with the shell's lower cavity is communicated, the baffle fixedly connected with the shell through fixed connection injection gas frame, the injection gas frame fixedly connected and communicated with the same number of gas bag of filter core, the gas bag is located in corresponding filter core, the shell is provided for the obturation assembly of a plurality of filter core.

[0007] More preferably, the obturation assembly includes a first drive member fixedly connected to the shell, the telescopic end of the first drive member is sealingly and slidingly connected to the shell, the injection gas frame is slidingly connected with an obturation frame, the obturation frame is fixedly connected to the telescopic end of the first drive member, and the obturation frame is in close contact with the baffle to obturate a plurality of filter cores.

[0008] More preferably, the fixed plate is rotationally connected with a number of rotating frames equal to the number of filter cores, the filter cores are located inside the corresponding rotating frames, the rotating frames are provided with scrapers in close contact with adjacent filter cores, and the fixed plate is provided with a drive assembly for driving all rotating frames to rotate.

[0009] More preferably, the drive assembly includes a second drive member fixedly connected to the shell, the rotating frames are fixedly connected with first gears, the fixed plate is rotationally connected with second gears meshing with all first gears, the second gears are fixedly connected with rotating shafts, and the rotating shafts are in transmission connection with the output shaft of the second drive member.

[0010] More preferably, the rotating shafts are fixedly connected with a number of inner plates in annular array, and the inner plates are used to push the liquid medicine in the middle part of the upper cavity of the shell.

[0011] More preferably, the fixed plate is rotationally connected with a gear ring, the gear ring is meshing with all first gears, the gear ring is fixedly connected with a number of outer plates in annular array, and the outer plates are used to push the liquid medicine at the edge of the upper cavity of the shell.

[0012] More preferably, the rotating frames are slidingly connected with adjacent scrapers, the baffle is slidingly connected with a sliding plate, the sliding plate is rotationally connected with a number of rotating rings equal to the number of filter cores, the scrapers are fixedly connected with drive blocks, and the rotating rings are slidingly connected with adjacent drive blocks.

[0013] More preferably, the partition plate and the shell are jointly connected with a rotating ring, the outer plates are jointly fixedly connected with the rotating ring, the inner side of the rotating ring is fixedly connected with an extrusion block, the sliding plate is provided with a groove, and the extrusion block is located in the groove and slides.

[0014] More preferably, the groove is composed of two trapezoidal grooves and two arc grooves which are alternately connected in a head-to-tail mode.

[0015] Compared with the prior art, the present application has the following advantages: 1. The auxiliary material system in the composition, especially the DL-malic acid, can adjust the release rate of the drug, and provides a physical and chemical basis for realizing the sustained-release effect, so that the drug can be released more gently in the body, and the effective blood drug concentration can be maintained for a longer time, thereby realizing the purpose of continuously supplying energy to myocardial cells, and overcoming the defects of short half-life and non-sustained drug effect in the prior art.

[0016] 2. By blocking the filter cores, the communication state of the upper and lower cavities of the shell is cut off, and the gas bag is inflated to push the medicinal liquid in the filter cores to enter the upper cavity of the shell again, so that back-flushing cleaning of the filter cores is realized, thereby prolonging the service life of the filter cores and reducing the replacement frequency of the filter cores.

[0017] 3. By rotating the scraper around the adjacent filter cores, the scraper scrapes off the impurities attached to the outside of the filter cores, and the inner plate and the outer plate rotate in opposite directions, so that the medicinal liquid on the inner and outer sides of the upper cavity of the shell rotates in opposite directions, and the two rotating medicinal liquids form a butt-joint force, thereby impacting the filter core located in the middle and further cleaning the impurities attached to the outside of the filter core.

[0018] 4. By rotating the scraper around the adjacent filter cores to scrape off the impurities on the outside of the filter cores, the scraper is periodically separated from the outside of the adjacent filter cores, a gap is formed between the scraper and the adjacent filter cores, the impurities accumulated on the front side of the scraper are separated from the filter core along the gap, and the impurity attachment rate on the outside of the filter core is further reduced. BRIEF DESCRIPTION OF DRAWINGS

[0019] Figure 1 It is a schematic diagram of the three-dimensional structure of the present application; Figure 2 It is a schematic diagram of the three-dimensional structure of the shell of the present application; Figure 3 It is a schematic diagram of the three-dimensional structure of the gas injection frame and the gas bag of the present application; Figure 4 It is a schematic diagram of the three-dimensional structure of the rotating frame and the first gear of the present application; Figure 5 It is a schematic diagram of the three-dimensional structure of the inner plate of the present application; Figure 6 It is a schematic diagram of the three-dimensional structure of the sliding plate of the present application; Figure 7 A sectional view of the spacer of the present application is shown in the figure; Figure 8 A sectional view of the spacer of the present application is shown in the figure; Figure 6 An enlarged sectional view of the spacer of the present application is shown in the figure; Figure 9 An exploded view of the sliding plate and the rotating ring of the present application is shown in the figure; Figure 10 A sectional view of the trapezoidal groove and the arc-shaped groove of the present application is shown in the figure.

[0020] In the above figures, the following reference signs are used: 1, housing; 2, liquid inlet pipe; 3, liquid outlet pipe; 4, sewage pipe; 5, spacer; 6, fixed plate; 7, filter core; 8, gas injection frame; 9, air bag; 10, first driving member; 11, blocking frame; 201, rotating frame; 202, scraper; 203, second driving member; 204, first gear; 205, second gear; 206, rotating shaft; 301, inner plate; 302, gear ring; 303, outer plate; 401, sliding plate; 402, rotating ring; 403, driving block; 501, rotating ring; 502, extrusion block; 503, groove; 5031, trapezoidal groove; 5032, arc-shaped groove. DETAILED DESCRIPTION

[0021] It is first to be noted that in the various described embodiments identical parts are provided with identical reference signs or identical component names, wherein the disclosure contained in the entire description is to be transferred by its meaning to identical parts provided with identical reference signs or identical component names. The chosen position indications in the description, for example, upper, lower, lateral, and the like, also refer to the directly described and shown figures and are transferred by their meaning to the new position in case of a change of position.

[0022] The currently clinically used levocarnitine ordinary oral liquid or injection has obvious limitations: its half-life is short, it is difficult to maintain stable blood drug concentration, frequent administration is required, and patient compliance is poor; the drug is metabolized quickly after absorption, cannot be long-acting accumulated in myocardial tissue, and limits the continuous improvement of myocardial energy metabolism; at the same time, insufficient targeting leads to uneven distribution of the drug in the whole body, and low effective concentration in myocardium, affecting the overall efficacy. Example 1

[0023] The present embodiment provides a sustained-release pharmaceutical composition for treating cardiomyopathy, which can release the drug more gently in the body.

[0024] Each 10 ml of the pharmaceutical composition comprises, raw drug: levocarnitine 1 g, auxiliary drug: sodium benzoate 48 mg, DL-malic acid 34 mg, sodium saccharin 5 mg, hydrochloric acid for adjusting the PH value to 4.3-4.7, purified water, and adding to 10 ml.

[0025] In the above scheme, levocarnitine is a key carrier of myocardial cell energy metabolism. In the state of cardiomyopathy (such as dilated cardiomyopathy, ischemic cardiomyopathy), exogenous supplementation of levocarnitine can transport long-chain fatty acids from the cytoplasm to the mitochondrial matrix for beta-oxidation, promote mitochondrial energy production, generate more adenosine triphosphate (ATP), provide energy support for the failing myocardium, and regulate the ratio of coenzyme A / acyl coenzyme A in mitochondria, optimize the metabolism of substances such as sugars, and the concentration of 1g / 10ml provides an effective therapeutic dose, which can not only achieve the expected blood drug concentration to play a heart-protecting role, but also ensure that the volume of the preparation is moderate, which is convenient for patients to accurately measure and take, and sodium benzoate as an effective preservative can prevent the liquid preparation from being contaminated by microorganisms during storage and use, DL-malic acid naturally masks the inherent bad taste of levocarnitine, and improves the oral palatability of the preparation, sodium saccharin as a high-intensity sweetener is used to further correct the taste of the preparation, and hydrochloric acid is used to accurately adjust the final pH value of the preparation, and the final pH value adjustment target is 4.5. Example 2

[0026] The present embodiment provides a sustained-release pharmaceutical composition preparation device for treating cardiomyopathy, which can reduce the maintenance frequency.

[0027] In the process of drug preparation, after the drug is dissolved and mixed, the mixed liquid needs to be filtered to remove internal impurities and polymers, so as to ensure the purity and quality of the drug liquid. The security filter is often used as a pre-filtering device in drug preparation, and its main function is to intercept larger particulate matter to prevent impurities from entering the subsequent process system. However, in actual use, impurities are easily attached to the outside of the filter cartridge, gradually forming a filter cake layer, which leads to a decrease in filtering efficiency, and thus the internal filter cartridge needs to be replaced regularly. This not only wastes time and effort, but also leads to a decrease in drug filtration rate, affecting the overall production efficiency.

[0028] As Figures 1-3As shown, it comprises a shell 1, the shell 1 is fixedly connected with a liquid inlet pipe 2, a liquid outlet pipe 3 and a blowdown pipe 4, the liquid inlet pipe 2, the liquid outlet pipe 3 and the blowdown pipe 4 are located at the upper part, the lower part and the bottom of the shell 1 respectively, a partition plate 5 and a fixed plate 6 are fixedly connected in the shell 1, the partition plate 5 and the fixed plate 6 are located at the lower part and the upper part in the shell 1 respectively, a plurality of filter cartridges 7 in annular array are detachably connected between the partition plate 5 and the fixed plate 6, the partition plate 5 divides the shell 1 into two cavities, the upper and lower cavities of the shell 1 are communicated through the plurality of filter cartridges 7, the liquid medicine enters the lower cavity of the shell 1 from the upper cavity of the shell 1 through the plurality of filter cartridges 7, so as to realize the filtration of the medicine, the liquid inlet pipe 2 is communicated with the upper cavity of the shell 1, the blowdown pipe 4 is communicated with the upper cavity of the shell 1 through the partition plate 5, the blowdown pipe 4 is initially in a closed state, the liquid inlet pipe 2 is used for injecting unfiltered liquid medicine into the upper cavity of the shell 1, the blowdown pipe 4 is used for discharging impurities stored in the upper cavity of the shell 1, the liquid outlet pipe 3 is communicated with the lower cavity of the shell 1, and the liquid outlet pipe 3 is used for discharging filtered liquid medicine, the lower side of the partition plate 5 is fixedly connected with a gas injection frame 8 which is fixedly connected with the shell 1, the gas injection frame 8 is communicated with a gas injection device outside, the gas injection frame 8 is fixedly connected and communicated with a plurality of gas bags 9 which are the same in number as the filter cartridges 7, the cross section of the gas bag 9 is annular, the central axis of the filter cartridge 7 coincides with the central axis of the adjacent gas bag 9, the gas bag 9 is located in the corresponding filter cartridge 7, and the gas bag 9 is in a contracted state in the initial state and does not affect the liquid medicine passing through the filter cartridge 7 to enter the lower cavity of the shell 1, when the gas bag 9 expands, the liquid medicine in the filter cartridge 7 can be pushed to flow reversely into the upper cavity of the shell 1, so as to realize the backflushing of the liquid medicine to the filter cartridge 7, prolong the service life of the filter cartridge 7 and reduce the replacement frequency, and a plugging assembly for plugging the plurality of filter cartridges 7 is arranged in the shell 1.

[0029] As shown in the figure, Figures 1-3 The plugging assembly comprises a first driving member 10, the first driving member 10 is fixedly connected to the bottom of the shell 1, the first driving member 10 is an electric push rod, the telescopic end of the first driving member 10 is sealingly and slidingly connected with the shell 1, the gas injection frame 8 is slidingly connected with a plugging frame 11, the plugging frame 11 is fixedly connected with the telescopic end of the first driving member 10, the telescopic end of the first driving member 10 can drive the plugging frame 11 to move up and down, and the plugging frame 11 is attached to the partition plate 5 to plug the plurality of filter cartridges 7, so as to isolate the communication between the filter cartridges 7 and the lower cavity of the shell 1.

[0030] Working principle: when the drug liquid needs to be filtered, the staff pours the drug liquid into the upper cavity of the shell 1 through the liquid inlet pipe 2, and continues to pour the drug liquid into the upper cavity of the shell 1 through the liquid inlet pipe 2 until the upper cavity of the shell 1 is filled with the drug liquid. At this moment, the drug liquid in the upper cavity of the shell 1 begins to pass through the filter element 7 under the action of pressure, and the filter element 7 filters the drug liquid during the process. The filtered drug liquid flows downward along the filter element 7 into the lower cavity of the shell 1, and the drug liquid in the lower cavity of the shell 1 is discharged from the liquid outlet pipe 3, thereby realizing the filtration of the drug liquid. The above steps are repeated until the filtration of the drug liquid is completed, and then the injection of the drug liquid is stopped.

[0031] When the filter element 7 needs to be cleaned, the staff opens the first driving element 10, the telescopic end of the first driving element 10 drives the blocking frame 11 to move upward, so that the blocking frame 11 is attached to the lower side of the partition plate 5, thereby blocking the filter element 7, and the injection of the drug liquid into the upper cavity of the shell 1 is stopped. At this moment, the upper and lower cavities of the shell 1 are in a state of being separated, and the inside of the filter element 7 contains the drug liquid. Then, the external gas injection device is opened, and the gas enters the gas bag 9 through the gas injection frame 8. The gas drives the gas bag 9 to start to expand, and the sewage pipe 4 is opened at the same time. The expansion of the gas bag 9 pushes the drug liquid in the adjacent filter element 7, so that the drug liquid forms a backflush to the filter element 7. The above steps are repeated until the gas bag 9 is expanded to be attached to the inside of the filter element 7. Then, the external gas injection device is closed. At this moment, the drug liquid in the upper cavity of the shell 1 carries the impurities backflushed from the filter element 7 and is discharged from the sewage pipe 4. By blocking the filter element 7, the communication state between the upper and lower cavities of the shell 1 is separated, and the drug liquid in the filter element 7 is pushed into the upper cavity of the shell 1 again by the expansion of the gas bag 9, thereby realizing the backflush cleaning of the filter element 7. In this way, the service life of the filter element 7 is prolonged, and the replacement frequency of the filter element 7 is reduced.

[0032] During the backflushing process of the filter element 7 by the gas bag 9, the drug liquid in the upper cavity of the shell 1 carries the impurities and is gradually discharged to the outside along the partition plate 5 and the sewage pipe 4. The above steps are repeated until the drug liquid in the upper cavity of the shell 1 is completely discharged. Then, the first driving element 10 and the external gas injection device are opened. The telescopic end of the first driving element 10 drives the blocking frame 11 to reset to the initial state downward, and the gas injection device extracts the gas in the gas bag 9 to make the gas bag 9 shrink to the initial state. When the filtration of the drug liquid is still needed, the drug liquid is injected into the liquid inlet pipe 2 again, and the above steps are repeated. Example 3

[0033] The embodiment provides a sustained-release drug composition preparation device for treating cardiomyopathy, which is further improved on the basis of example 2.

[0034] In the backwashing process of the filter element 7, the impurities attached to the outside of the filter element 7 are difficult to completely detach from the surface of the filter element due to the influence of surface tension and interparticle interaction force. Although the backwashing force can remove some loose impurities to a certain extent, the separation effect is limited for tightly attached impurities. These residual impurities continue to adhere to the outside of the filter element 7, resulting in a gradual decrease in the effective filtration area of the filter element, an increase in the filtration resistance, and a significant impact on the filtration efficiency of the filter element 7 for the medicinal liquid.

[0035] As shown in Figure 2 and Figures 4-6 , the fixed plate 6 is rotatably connected with a number of rotating frames 201 equal to the number of filter elements 7. The filter element 7 is located inside the corresponding rotating frame 201, the center axis of the rotating frame 201 coincides with the center axis of the adjacent filter element 7, and the rotating frame 201 is provided with a scraper 202 abutting against the adjacent filter element 7. The scraper 202 is used to rotate around the filter element 7 and scrape off the impurities attached to the outside. The fixed plate 6 is provided with a driving assembly for driving all rotating frames 201 to rotate. The driving assembly includes a second driving member 203, which is a servo motor. The top of the rotating frame 201 is fixedly connected with a first gear 204. The fixed plate 6 is rotatably connected with a second gear 205 meshing with all first gears 204. The second gear 205 is fixedly connected with a rotating shaft 206, which is in transmission connection with the output shaft of the second driving member 203. The output shaft of the second driving member 203 drives all scrapers 202 to rotate through the rotating shaft 206, the first gear 204, all second gears 205 and all rotating frames 201.

[0036] As shown in Figure 4 and Figure 5 , the rotating shaft 206 is fixedly connected with a number of inner plates 301 arranged in a ring array on the outside. The inner plates 301 are used to push the medicinal liquid in the middle part of the upper cavity of the housing 1. When the rotating shaft 206 rotates, it can drive the number of inner plates 301 on it to rotate synchronously. The lower side of the fixed plate 6 is rotatably connected with a gear ring 302, which is meshed with all first gears 204. The rotating shaft 206 can drive the gear ring 302 to rotate through the first gear 205, all second gears 204. The rotating direction of the rotating shaft 206 and the gear ring 302 is opposite. The gear ring 302 is fixedly connected with a number of outer plates 303 arranged in a ring array. The outer plates 303 are used to push the medicinal liquid at the edge of the upper cavity of the housing 1, i.e. the rotating direction of the outer plates 303 is opposite to that of the inner plates 301. The inner plates 301 and the outer plates 303 are respectively located in the middle part and the edge of the upper cavity of the housing 1, so that the medicinal liquid at the middle part and the edge of the upper cavity of the housing 1 rotates in opposite directions, and the two rotating medicinal liquids form a counterforce.

[0037] Working principle: when the air bag 9 to the filter core 7 complete the back flush, first close the drain pipe 4, at this moment open the second drive element 203, make the output shaft of the second drive element 203 drive the rotating shaft 206 rotation, the rotating shaft 206 drive the second gear 205 on it start to rotate, the second gear 205 through all the first gear 204 drive all the rotating frame 201 rotation, rotating frame 201 drive the scraper 202 on it start to rotate around the adjacent filter core 7, make the scraper 202 scrape the impurities attached to the outside of the filter core 7, and in the rotating shaft 206 drive the second gear 205 rotation period, the rotating shaft 206 drive the synchronous rotation of the annular array of the inner plate 301 on it, make the annular array of several inner plate 301 agitate the drug solution in the middle of the upper cavity of the shell 1, at the same time the rotating shaft 206 through the second gear 205 and all the first gear 204 drive the gear ring 302 rotation, and the second gear 205 and the gear ring 302 rotation direction is opposite, the gear ring 302 drive the synchronous rotation of the annular array of the outer plate 303, make the annular array of the outer plate 303 drive the drug solution on the edge of the upper cavity of the shell 1 rotation, by making the drug solution on the inside and outside of the upper cavity of the shell 1 rotation in opposite directions, the two rotating drug solution form the impact force, and then realize the impact on the filter core 7 located in the middle, further clean the impurities attached to the outside of the filter core 7.

[0038] When the second drive element 203 is opened for a set time, the second drive element 203 is closed, and the drain pipe 4 is opened, and then the drug solution in the upper cavity of the shell 1 carries the impurities out along the drain pipe 4, and so on until the drug solution in the upper cavity of the shell 1 is completely discharged. When the filter core 7 needs to be cleaned again, repeat the above steps. Example 4

[0039] The embodiment provides a sustained-release pharmaceutical composition preparation device for treating cardiomyopathy, which is further improved based on example 3.

[0040] When the scraper 202 rotates around the adjacent filter core 7, the pushing side of the scraper 202 will continuously accumulate impurities that are difficult to separate effectively. Because there is strong adhesion between the impurities on the surface of the filter core 7 and the scraper 202, these residual impurities cannot completely separate from the filter core 7 and will eventually still adhere to the outside of the filter core. This not only reduces the filtering efficiency of the filter core 7, but also may cause the filter core to be blocked, affecting the filtering effect of the drug solution.

[0041] As Figure 4 , Figure 5 and Figures 6-10As shown, the rotating frame 201 is slidingly connected with the adjacent scraper 202, that is, the scraper 202 can slide outward along the adjacent rotating frame 201 to separate the scraper 202 from the rotating frame 201. The baffle 5 is slidingly connected with a sliding plate 401. The sliding plate 401 is rotationally connected with rotating rings 402 which are the same in number as the filter cartridges 7. The bottom of the scraper 202 is fixedly connected with a driving block 403. The rotating ring 402 is slidingly connected with the adjacent driving block 403. The scraper 202 can drive the rotating ring 402 to rotate synchronously through the driving block 403 when rotating. The sliding plate 401 can move upward synchronously through the rotating ring 402 and the rotating ring 402 thereon. The rotating ring 402 slides along the adjacent driving block 403, so as to realize that the driving block 403 drives the scraper 202 to slide along the adjacent rotating frame 201. The upper side of the baffle 5 and the inner side of the shell 1 are rotationally connected with a rotating ring 501. The bottoms of the plurality of outer plates 303 are fixedly connected with the rotating ring 501. The outer plate 303 can drive the rotating ring 501 to rotate synchronously. The inner side of the rotating ring 501 is fixedly connected with two symmetrically distributed extrusion blocks 502. The sliding plate 401 is provided with a groove 503. The extrusion block 502 slides in the groove 503. The groove 503 is composed of two trapezoidal grooves 5031 and two arc grooves 5032 which are alternately connected in a head-to-tail manner. When the extrusion block 502 slides along the arc groove 5032, the sliding plate 401 is at the lowest position. At this moment, the scraper 202 and the adjacent filter cartridge 7 are in a state of adhesion. When the extrusion block 502 slides along the trapezoidal groove 5031, the sliding plate 401 changes from the lowest position to the highest position and maintains for a certain period of time and then changes from the highest position to the lowest position. During this period, the scraper 202 and the adjacent filter cartridge 7 change from adhesion to separation and then change from separation to adhesion.

[0042] Working principle: in the process of rotating shaft 206 driving the gear ring 302 to rotate through the second gear 205 and a plurality of first gears 204, the gear ring 302 drives the rotating ring 501 to rotate synchronously through a plurality of outer plates 303. The rotating ring 501 drives the two symmetrically distributed extrusion blocks 502 thereon to rotate synchronously. The two symmetrically distributed extrusion blocks 502 slide along the groove 503 on the sliding plate 401, so that the two extrusion blocks 502 drive the sliding plate 401 to move upward through the groove 503 periodically. When the sliding plate 401 moves upward, all the rotating rings 402 thereon move synchronously. The rotating ring 402 moves upward to push the adjacent driving block 403, so that the driving block 403 drives the adjacent scraper 202 to slide outward along the rotating frame 201. The scraper 202 is separated from the adjacent filter cartridge 7, so that a gap is generated between the scraper 202 and the adjacent filter cartridge 7. The gap is impacted by the liquid medicine, so as to ensure the treatment effect of the impurities on the filter cartridge 7.

[0043] Thus, when the sliding plate 401 moves downward, all the rotating rings 402 on the sliding plate 401 move downward synchronously, the rotating rings 402 drive the adjacent scrapers 202 to slide inward along the adjacent rotating frames 201 through the driving blocks 403, and the above steps are repeated continuously until the second driving member 203 is closed.

[0044] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, but not to limit the protection scope of the present application. Although the present application has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present application can be modified or replaced equivalently without departing from the essence and scope of the technical solutions of the present application.

Claims

1. A sustained release pharmaceutical composition for treating cardiomyopathy, characterized by, Each 10ml pharmaceutical composition includes, raw materials: Levocarnitine 1g, auxiliary drug: sodium benzoate 48mg, DL-malic acid 34mg, sodium saccharin 5mg, hydrochloric acid, for adjusting PH value to 4.3-4.7, purified water, add to 10ml.

2. A sustained-release drug preparation device for treating cardiomyopathy, comprising a shell (1), a liquid inlet pipe (2), a liquid outlet pipe (3) and a sewage pipe (4) fixedly connected to the shell (1), a partition plate (5) and a fixed plate (6) fixedly connected in the shell (1), a plurality of filter cartridges (7) in annular array detachably connected between the partition plate (5) and the fixed plate (6), the partition plate (5) dividing the shell (1) into two cavities, the upper and lower cavities of the shell (1) being communicated through the filter cartridges (7), the liquid inlet pipe (2) being communicated with the upper cavity of the shell (1), the sewage pipe (4) being communicated with the upper cavity of the shell (1) through the partition plate (5), and the liquid outlet pipe (3) being communicated with the lower cavity of the shell (1), characterized in that: The partition plate (5) is fixedly connected with an air injection frame (8) which is fixedly connected through the shell (1), the air injection frame (8) is fixedly connected and communicated with the same number of air bags (9) as the filter core (7), the air bag (9) is located in the corresponding filter core (7), and the shell (1) is provided with a blocking assembly for blocking a plurality of filter cores (7).

3. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 2, wherein the device is a tablet. The blocking assembly comprises a first driving member (10) which is fixedly connected to the shell (1), and the telescopic end of the first driving member (10) is sealingly and slidingly connected to the shell (1), the air injection frame (8) is slidingly connected with a blocking frame (11), the blocking frame (11) is fixedly connected with the telescopic end of the first driving member (10), and the blocking frame (11) is attached to the partition plate (5) to block a plurality of filter cores (7).

4. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 3, wherein the device is a tablet. The fixed plate (6) is rotatably connected with the same number of rotating frames (201) as the filter core (7), the filter core (7) is located in the inside of the corresponding rotating frame (201), the rotating frame (201) is provided with a scraper (202) attached to the adjacent filter core (7), and the fixed plate (6) is provided with a driving assembly for driving all the rotating frames (201) to rotate.

5. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 4, wherein the device is a tablet. The driving assembly comprises a second driving member (203) which is fixedly connected to the shell (1), the rotating frame (201) is fixedly connected with a first gear (204), the fixed plate (6) is rotatably connected with a second gear (205) which is engaged with all the first gears (204), the second gear (205) is fixedly connected with a rotating shaft (206), and the rotating shaft (206) is in transmission connection with the output shaft of the second driving member (203).

6. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 5, wherein the device is a tablet. The rotating shaft (206) is fixedly connected with a plurality of inner plates (301) in annular array, and the inner plates (301) are used for pushing the medicinal liquid in the middle part of the cavity of the shell (1).

7. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 5, wherein the device is a tablet. The fixed plate (6) is rotatably connected with a gear ring (302) which is engaged with all the first gears (204), and the gear ring (302) is fixedly connected with a plurality of outer plates (303) in annular array, and the outer plates (303) are used for pushing the medicinal liquid at the edge of the cavity of the shell (1).

8. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 5, wherein the device is a tablet. The rotating frame (201) is slidingly connected with the adjacent scraper (202), the partition plate (5) is slidingly connected with a sliding plate (401), the sliding plate (401) is rotatably connected with the same number of rotating rings (402) as the filter core (7), the scraper (202) is fixedly connected with a driving block (403), and the rotating ring (402) is slidingly connected with the adjacent driving block (403).

9. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 7, wherein the device is a tablet. The partition (5) and the shell (1) are jointly connected with a rotating ring (501), a plurality of the outer plates (303) are jointly fixed with the rotating ring (501), the inner side of the rotating ring (501) is fixedly connected with an extrusion block (502), the sliding plate (401) is provided with a groove (503), and the extrusion block (502) is located in the groove (503) and slides.

10. The device for preparing a sustained-release pharmaceutical composition for treating cardiomyopathy according to claim 9, wherein the device is a tablet. The groove (503) is composed of two trapezoidal grooves (5031) and two arc grooves (5032) which are alternately connected in a head-to-tail mode.

Images